The result showed that levels of NT-proBNP dropped 23% (p=0.005) over 12 weeks but only by 15% (p=0.20) over 36 weeks among those receiving LCZ696 compared with valsartan.
LCZ696 was effective for the primary [natriuretic-peptide] end point in every single one of the subgroups tested. But there was one subgroup in which [LCZ696] was more effective. There was a significant interaction in patients with diabetes.
NYHA class also improved significantly with LCZ696 (p<0.05) at 36 weeks, as did left atrial width (p=0.03), left atrial volume (p=0.003), and left atrial volume index (p=0.007).
In conclusion, this is an initial positive trial showing some benefits of a new dual RAAS inhibition in HF-PSF, and surely will trigger a definitive larger trial.
Published online August 26, 2012 in the Lancet. And presented at the European Society of Cardiology (ESC) 2012 Congress